Commercial clinical trials in the UK: the Lord O’Shaughnessy review
Final report of the independent review of UK commercial clinical trials, and government response.
Documents
Details
In February 2023, the government commissioned an independent review to offer recommendations on how to resolve key challenges in conducting commercial clinical trials in the UK and transform the UK commercial clinical trial environment. The review sets out 27 recommendations, including both priority actions to progress in 2023 and longer-term ambitions for UK commercial clinical trials.
The review was conducted by Lord James O’Shaughnessy, Senior Partner at consultancy firm Newmarket Strategy, Board Member of Health Data Research UK (HDR UK) and former Health Minister, who was appointed as review Chair. During the review, Lord O’Shaughnessy consulted closely with industry and a wide range of stakeholders across the UK clinical trials sector.
The government response welcomes all recommendations from the review, in principle, and makes 5 headline commitments backed by £121 million. An implementation update, setting out progress made against these commitments and a comprehensive response to the remaining recommendations, will be published in the autumn.
Updates to this page
Published 25 May 2023Last updated 26 May 2023 + show all updates
-
Deleted sentence beginning ‘Contract values will be agreed once with a lead site on behalf of the whole NHS' as it repeated information given earlier in the section.
-
First published.